Wells Fargo & Company Alzamend Neuro, Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.19 - $0.52 $14 - $39	76 Added 18.14%	495 $0
Q2 2023 Aug 15, 2023	BUY	$0.49 - $0.77 $9 - $14	19 Added 4.75%	419 $0
Q1 2023 May 12, 2023	SELL	$0.37 - $0.71 $366 - $702	-990 Reduced 71.22%	400 $0
Q4 2022 Feb 13, 2023	BUY	$0.53 - $222.0 $535 - $224,220	1,010 Added 265.79%	1,390 $0
Q3 2022 Nov 14, 2022	BUY	$0.88 - $178.5 $334 - $67,830	380 New	380 $0
Q3 2021 Nov 15, 2021	SELL	$2.28 - $7.68 $440 - $1,482	-193 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$8.12 - $13.5 $1,567 - $2,605	193 New	193 $2,000

Ticker ALZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,481,800
Market Cap $159M
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.